Posted by Michael Wonder on 01 Jun 2020
Boehringer Ingelheim receives positive CHMP opinion for a third nintedanib indication in pulmonary fibrosis
29 May 2020 - The opinion is for the treatment of adults with other chronic fibrosing interstitial lung diseases with a progressive phenotype beyond idiopathic pulmonary fibrosis.
Boehringer Ingelheim today announced that the CHMP of the EMA has adopted a positive opinion recommending an additional indication for nintedanib in adults for the treatment of other chronic fibrosing interstitial lung diseases with a progressive phenotype beyond IPF.
The opinion is based on the positive results of the INBUILD phase III trial, the first study to evaluate patients with a broad range of chronic fibrosing interstitial lung diseases and a progressive disease behaviour.
